TY - JOUR
AU1 - Yasuda, Takushi
AB - Ann Surg Oncol (2018) 25:2127–2128 https://doi.org/10.1245/s10434-018-6544-0 ED ITORIA L – G A STROI N TESTIN A L O NCOL OG Y Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy Takushi Yasuda, MD Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka , Japan The main goals of neoadjuvant therapy are to increase A review of the role and position of chemotherapy in the curative resection rate by downstaging the primary multimodality therapy would be timely. The findings of tumor and to improve postoperative survival by eliminating several randomized clinical studies comparing neoadjuvant systemic micrometastases. Chemoradiotherapy (CRT), the CRT and NAC are currently under way and will provide mainstay of preoperative therapy for advanced esophageal some guidance in this regard. cancer in Western countries, has dramatically improved Chemotherapy is the only treatment method that can be local control by increasing the R0 resection rate. However, used to control the systemic spread of esophageal cancer. distant metastasis is common, and two recent randomized However, systemic micrometastases cannot always be clinical studies comparing neoadjuvant CRT and neoadju- eliminated by two or three courses of NAC, and vant chemotherapy (NAC) 
TI - Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy
JF - Annals of Surgical Oncology
DO - 10.1245/s10434-018-6544-0
DA - 2018-05-29
UR - https://www.deepdyve.com/lp/springer-journals/future-treatment-strategy-for-esophageal-cancer-based-on-prediction-of-DyTjPeYwbZ
SP - 2127
EP - 2128
VL - 25
IS - 8
DP - DeepDyve
ER -